PA-001 Ph.1 Study in Healthy and Elderly Subjects

This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts. The principal aim of this study was to obtain safety and tolerability data when PA-001 is administered IV as single and multiple doses to healthy subjects. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The study also investigated the effects of age on the PK of PA-001 prior to patient studies.

NCT Number	NCT07518771
Lead Sponsor	PeptiDream Inc. Collaborators: PeptiAID Inc.
Conditions	COVID - 19
Enrollment	47 participants
Start Date	2024-07-30
Primary Completion	2025-06-02 (estimated)
Study Completion	2025-06-02 (estimated)
Updated on ClinicalTrials.gov	2026-04-09